Company Profile

Accium Biosciences Inc
Profile last edited on: 9/28/16      CAGE: 4SVX6      UEI: YTE6FKCGGHN9

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

550 17th Avenue Suite 550
Seattle, WA 98122
   (206) 258-8860
Location: Single
Congr. District: 09
County: King

Public Profile

Accium BioSciences provides accelerator mass spectrometry (AMS) services to the global pharmaceutical and life science industries: pharmacokinetics, metabolism and mass balance. AMS is an ultrasensitive detection platform capable of quantifying 14C-labeled molecules in the 0.001-100 DPM/mL range. Accium launched the first commercial AMS facility in North America in early 2006.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 1 NIH $102,900
Project Title: Patient-Specific Therapy Of Glioblastoma Using A Lightly-Labeled [14c]-Temozolomi

Key People / Management

  Glenn Kawasaki -- President, Ceo

  Barbara Alford-Cassel -- Vice President

  Ali Arjomand -- Former President

  Julie Zalikowski -- Director Bioanalytical

Company News

There are no news available.